Common new active substance approvals across major regulatory authorities (multi-year total) vs Sales growth at constant exchange rates

Common new active substance approvals across major regulatory authorities (multi-year total) and Sales growth at constant exchange rates worldwide, compared over time.

Change the pair

Compare different indicators

The series

Over time

Global, spaced by time . Different units, drawn on separate scales and clipped to the years both series publish — earlier history stays on each indicator's own page. Read the values, not the heights.

Common new active substance approvals across major regulatory authorities (multi-year total)

Unit: count · 2 observations

Line chart
Common new active substance approvals across major regulatory authorities (multi-year total)Common new active substance approvals across major regulatory authorities (multi-year total). 2 observations from 2016–2020 to 2021–2025, ranging from 37 to 52. Latest value 52 (2021–2025). 0 10 20 30 40 50 60 2016 2018 2020 2022 2024 2026 37 52
Common new active substance approvals across major regulatory authorities (multi-year total)Common new active substance approvals across major regulatory authorities (multi-year total). 2 observations from 2016–2020 to 2021–2025, ranging from 37 to 52. Latest value 52 (2021–2025). 0 20 40 60 2016 2018 2020 2022 2024 2026 37 52
Common new active substance approvals across major regulatory authorities (multi-year total)Common new active substance approvals across major regulatory authorities (multi-year total). 2 observations from 2016–2020 to 2021–2025, ranging from 37 to 52. Latest value 52 (2021–2025). 0 20 40 60 2016 2018 2020 2022 2024 2026 37 52
View the underlying data
Common new active substance approvals across major regulatory authorities (multi-year total)
Period Type Value
2016–2020 Actual 37
2021–2025 Actual 52
Source: CIRS · CC BY 4.0 · Full series

Sales growth at constant exchange rates

Unit: % · 2 observations

Line chart
Sales growth at constant exchange ratesSales growth at constant exchange rates. 2 observations from Q1 2026 to Q2 2026, ranging from 3% to 17.8%. Latest value 17.8% (Q2 2026). % 0 5 10 15 20 2016 2018 2020 2022 2024 2026 3% 18%
Sales growth at constant exchange ratesSales growth at constant exchange rates. 2 observations from Q1 2026 to Q2 2026, ranging from 3% to 17.8%. Latest value 17.8% (Q2 2026). % 0 5 10 15 20 2016 2018 2020 2022 2024 2026 3% 18%
Sales growth at constant exchange ratesSales growth at constant exchange rates. 2 observations from Q1 2026 to Q2 2026, ranging from 3% to 17.8%. Latest value 17.8% (Q2 2026). % 0 5 10 15 20 2016 2018 2020 2022 2024 2026 3% 18%
View the underlying data
Sales growth at constant exchange rates
Period Type Value
Q1 2026 Actual 3%
Q2 2026 Actual 17.8%
Source: Roche, Sanofi · CC BY 4.0 · Full series

Provenance

Where these numbers come from

Common new active substance approvals across major regulatory authorities (multi-year total)

Total count of new active substances approved across all designated major regulatory authorities during the period.

2 observations in Global · source organisations: CIRS

Sales growth at constant exchange rates

Percentage change in sales calculated at constant exchange rates over the specified period.

2 observations in Global · source organisations: Roche, Sanofi

Data published under CC BY 4.0. Series A as JSON · Series B as JSON

Keep exploring

Related